CLINICAL STUDY OF PULMONARY FUNCTION TESTS IN PATIENTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 2047-2054
AbstractBackground: The hallmark of COPD is airflow obstruction which is typically described by spirometry. Spirometry is a cost efficient method of ordering pulmonary function tests is to start with spirometry and then order further tests in a stepwise fashion to refine the diagnosis.Present study was aimed to study pulmonary function tests in patients of chronic obstructive pulmonary disease.
Material and Methods: Present study was Cross-sectional Observational Study, conducted in patients clinically diagnosed as COPD in OPD or admitted to our wards and having symptoms of COPD (dyspnea, chronic cough or sputum production).
Results: 100 COPD patients were studied, majority were from age group 50 to 59 years (41%) & age group 60 to 69 years (30%). The male to female ratio was 5.67:1. Mean post-bronchodilator FEV1 % predicted of males in the group was 53.81 ± 19.29) whereas mean FEV1 % predicted of females in the group was 51.26 ± 15.96. Mean post-bronchodilator FEV1/FVC ratio of males in the group was 0.433 ± 0.156 whereas mean FEV1/FVC ratio of females in the group was 0.411 ± 0.128. 15 patients were in GOLD Stage I (FEV1 ≥ 80% predicted) ,34 patients were in Stage II (50% ≤ FEV1 < 80 % predicted),36 patients were in stage III (30% ≤ FEV1 < 50 % predicted) whereas 15 patients were in stage IV( FEV1 < 30%). The difference between mean post-bronchodilator reversibility in FEV1 (in percentage) in patients in GOLD stage 1 vs stage 2 vs stage 3 vs stage 4 (applying ANOVA) was not found to be statistically significant (P=.869>0.05).
Conclusion: Spirometry is important tool in confirming and assessing severity of airway obstruction in COPD patients. Majority of COPD patients were in stage 2 & 3 (GOLD) of airway obstruction confirmed by spirometry.
- Article View: 67
- PDF Download: 71